Literature DB >> 12853462

Molecular background of progressive myoclonus epilepsy.

Anna-Elina Lehesjoki1.   

Abstract

Research on human inherited diseases provides a powerful tool to identify an intrinsically important subset of genes vital to healthy functioning of the organism. Progressive myoclonus epilepsies (PMEs) are a group of rare inherited disorders characterized by the association of epilepsy, myoclonus and progressive neurological deterioration. Significant progress has been made in elucidating the molecular background of PMEs. Here, progress towards understanding the molecular pathogenesis of PMEs is reviewed using the most common single cause of PME, Unverricht-Lundborg disease, as an example. Mutations in the gene encoding cystatin B (CSTB), a cysteine protease inhibitor, are responsible for the primary defect in Unverricht-Lundborg disease. CSTB-deficient mice, produced by targeted disruption of the mouse Cstb gene, display a phenotype similar to the human disease, with progressive ataxia and myoclonic seizures. The mice show neuronal atrophy, apoptosis and gliosis as well as increased expression of apoptosis and glial activation genes. Although significant advances towards understanding the molecular basis of Unverricht-Lundborg disease have been achieved, the physiological function of CSTB and the molecular pathogenesis of the disease remain unknown.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853462      PMCID: PMC165608          DOI: 10.1093/emboj/cdg338

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  67 in total

1.  Novel cystatin B mutation and diagnostic PCR assay in an Unverricht-Lundborg progressive myoclonus epilepsy patient.

Authors:  I N Bespalova; S Adkins; M Pranzatelli; M Burmeister
Journal:  Am J Med Genet       Date:  1997-09-19

2.  Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis.

Authors:  D E Sleat; R J Donnelly; H Lackland; C G Liu; I Sohar; R K Pullarkat; P Lobel
Journal:  Science       Date:  1997-09-19       Impact factor: 47.728

3.  Seizures induce widespread upregulation of cystatin B, the gene mutated in progressive myoclonus epilepsy, in rat forebrain neurons.

Authors:  E D'Amato; Z Kokaia; A Nanobashvili; M Reeben; A E Lehesjoki; M Saarma; O Lindvall
Journal:  Eur J Neurosci       Date:  2000-05       Impact factor: 3.386

4.  Characterization of the cystatin B gene promoter harboring the dodecamer repeat expanded in progressive myoclonus epilepsy, EPM1.

Authors:  K Alakurtti; K Virtaneva; T Joensuu; J J Palvimo; A E Lehesjoki
Journal:  Gene       Date:  2000-01-25       Impact factor: 3.688

5.  Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.

Authors:  S Ganesh; K L Agarwala; K Ueda; T Akagi; K Shoda; T Usui; T Hashikawa; H Osada; A V Delgado-Escueta; K Yamakawa
Journal:  Hum Mol Genet       Date:  2000-09-22       Impact factor: 6.150

6.  G to C transversion at a splice acceptor site causes exon skipping in the cystatin B gene.

Authors:  I N Bespalova; M Pranzatelli; M Burmeister
Journal:  Mutat Res       Date:  1997-09       Impact factor: 2.433

7.  Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.

Authors:  B A Minassian; J R Lee; J A Herbrick; J Huizenga; S Soder; A J Mungall; I Dunham; R Gardner; C Y Fong; S Carpenter; L Jardim; P Satishchandra; E Andermann; O C Snead; I Lopes-Cendes; L C Tsui; A V Delgado-Escueta; G A Rouleau; S W Scherer
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

8.  Transcriptional properties of RNA polymerase II within triplet repeat-containing DNA from the human myotonic dystrophy and fragile X loci.

Authors:  M A Parsons; R R Sinden; M G Izban
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

9.  CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis.

Authors:  M Savukoski; T Klockars; V Holmberg; P Santavuori; E S Lander; L Peltonen
Journal:  Nat Genet       Date:  1998-07       Impact factor: 38.330

10.  Nuclear localization of cystatin B, the cathepsin inhibitor implicated in myoclonus epilepsy (EPM1).

Authors:  M Riccio; R Di Giaimo; S Pianetti; P P Palmieri; M Melli; S Santi
Journal:  Exp Cell Res       Date:  2001-01-15       Impact factor: 3.905

View more
  12 in total

Review 1.  Evolutionary families of peptidase inhibitors.

Authors:  Neil D Rawlings; Dominic P Tolle; Alan J Barrett
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

2.  Neuronal transcriptome of Aplysia: neuronal compartments and circuitry.

Authors:  Leonid L Moroz; John R Edwards; Sathyanarayanan V Puthanveettil; Andrea B Kohn; Thomas Ha; Andreas Heyland; Bjarne Knudsen; Anuj Sahni; Fahong Yu; Li Liu; Sami Jezzini; Peter Lovell; William Iannucculli; Minchen Chen; Tuan Nguyen; Huitao Sheng; Regina Shaw; Sergey Kalachikov; Yuri V Panchin; William Farmerie; James J Russo; Jingyue Ju; Eric R Kandel
Journal:  Cell       Date:  2006-12-29       Impact factor: 41.582

3.  A distinct autosomal recessive ataxia maps to chromosome 12 in an inbred family from Jordan.

Authors:  Hatem El-Shanti; Azhar Daoud; Ammar A Sadoon; Suzanne M Leal; Shan Chen; Kwanghyuk Lee; Ronald Spiegel
Journal:  Brain Dev       Date:  2006-01-10       Impact factor: 1.961

Review 4.  Gene polymorphisms and their role in epilepsy treatment and prognosis.

Authors:  Ortrud K Steinlein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-06-16       Impact factor: 3.000

5.  A mutation in the Golgi Qb-SNARE gene GOSR2 causes progressive myoclonus epilepsy with early ataxia.

Authors:  Mark A Corbett; Michael Schwake; Melanie Bahlo; Leanne M Dibbens; Meng Lin; Luke C Gandolfo; Danya F Vears; John D O'Sullivan; Thomas Robertson; Marta A Bayly; Alison E Gardner; Annemarie M Vlaar; G Christoph Korenke; Bastiaan R Bloem; Irenaeus F de Coo; Judith M A Verhagen; Anna-Elina Lehesjoki; Jozef Gecz; Samuel F Berkovic
Journal:  Am J Hum Genet       Date:  2011-05-05       Impact factor: 11.025

6.  Stefin B interacts with histones and cathepsin L in the nucleus.

Authors:  Slavko Ceru; Spela Konjar; Katarina Maher; Urska Repnik; Igor Krizaj; Mojca Bencina; Miha Renko; Alain Nepveu; Eva Zerovnik; Boris Turk; Natasa Kopitar-Jerala
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

Review 7.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

Review 8.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

Review 9.  Protective mechanisms by cystatin C in neurodegenerative diseases.

Authors:  Sebastien Gauthier; Gurjinder Kaur; Weiqian Mi; Belen Tizon; Efrat Levy
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

10.  Cystatin C rescues degenerating neurons in a cystatin B-knockout mouse model of progressive myoclonus epilepsy.

Authors:  Gurjinder Kaur; Panaiyur Mohan; Monika Pawlik; Steven DeRosa; Jay Fajiculay; Shaoli Che; Anders Grubb; Stephen D Ginsberg; Ralph A Nixon; Efrat Levy
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.